At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Closed 11-04 16:00:00 EST
1.14
+0.06
+5.56%
盘后1.11
-0.03-2.63%
19:59 EST
High1.15Low1.09Vol267.45K
Open1.12D1 Closing1.08Amplitude5.50%
Mkt Cap70.39MTradable Cap63.04MTotal Shares61.74M
T/O300.92KT/O Rate0.48%Tradable Shares55.30M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Maia Biotech Completes Enrollment for THIO-101 Phase 2 NSCLC Trial of Ateganosine Plus Cemiplimab
Reuters  ·  10-07
Maia Biotech Completes Enrollment for THIO-101 Phase 2 NSCLC Trial of Ateganosine Plus Cemiplimab
Maia Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  10-07
Maia Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
MAIA Biotechnology Releases New Investor Presentation and Update
TIPRANKS  ·  10-06
MAIA Biotechnology Releases New Investor Presentation and Update
Diamond Equity releases update note on MAIA Biotechnology
TIPRANKS  ·  10-01
Diamond Equity releases update note on MAIA Biotechnology
MAIA Biotechnology files to sell 751,879 shares of common stock for holders
TIPRANKS  ·  09-26
MAIA Biotechnology files to sell 751,879 shares of common stock for holders
Maia Biotechnology - Selling Stockholder Offering 751,879 Shares of Maia Biotechnology Common Stock - SEC Filing
THOMSON REUTERS  ·  09-26
Maia Biotechnology - Selling Stockholder Offering 751,879 Shares of Maia Biotechnology Common Stock - SEC Filing
Maia Biotech Wins Spanish, Portuguese Regulatory Clearance to Screen Patients in THIO-104 Lung Cancer Trial
Reuters  ·  09-23
Maia Biotech Wins Spanish, Portuguese Regulatory Clearance to Screen Patients in THIO-104 Lung Cancer Trial
Maia Biotechnology Expands Pivotal Phase 3 Thio-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
THOMSON REUTERS  ·  09-23
Maia Biotechnology Expands Pivotal Phase 3 Thio-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
Maia Biotechnology - Targets 100 Patients Dosed in Thio-104 by Year-End 2026; Interim Analysis in 2027
THOMSON REUTERS  ·  09-23
Maia Biotechnology - Targets 100 Patients Dosed in Thio-104 by Year-End 2026; Interim Analysis in 2027
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
GlobeNewswire  ·  09-23
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
Maia Biotech Says Phase 3 THIO-104 Trial in Third-Line NSCLC Enrolls 65 Patients
Reuters  ·  09-22
Maia Biotech Says Phase 3 THIO-104 Trial in Third-Line NSCLC Enrolls 65 Patients
Maia Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  09-22
Maia Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
GlobeNewswire  ·  09-22
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Maia Biotechnology Wins $2.3 Million NIH Grant for Phase 2 NSCLC Trial Expansion
Reuters  ·  09-16
Maia Biotechnology Wins $2.3 Million NIH Grant for Phase 2 NSCLC Trial Expansion
Maia Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
THOMSON REUTERS  ·  09-16
Maia Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
GlobeNewswire  ·  09-16
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Maia Biotechnology Board Member Ramiro Guerrero Boosts Stake with USD 252,284 Share Buy
Reuters  ·  09-15
Maia Biotechnology Board Member Ramiro Guerrero Boosts Stake with USD 252,284 Share Buy
Maia Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
THOMSON REUTERS  ·  09-15
Maia Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
Maia Biotechnology - Directors and Officers Hold 21.34% Stake as of Sept 14, 2026
THOMSON REUTERS  ·  09-15
Maia Biotechnology - Directors and Officers Hold 21.34% Stake as of Sept 14, 2026
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
GlobeNewswire  ·  09-15
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--